Top

Diabetologia

Published in:

01-09-2019 | Breast Cancer | Article

The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study

Authors: Shiu Lun Au Yeung, Shan Luo, C. Mary Schooling

Published in: Diabetologia | Issue 9/2019

Abstract

Aims/hypothesis

Growth differentiation factor 15 (GDF-15), a suggested biomarker for metformin use, may explain the potential cardioprotective and anti-cancer properties of metformin. We conducted a Mendelian randomisation study to examine the role of GDF-15 in risk of coronary artery disease (CAD) and breast and colorectal cancer. Secondary analyses included examination of the association of GDF-15 with type 2 diabetes, glycaemic traits, BP, lipids and BMI.

Methods

We obtained SNPs strongly (p value <5 × 10⁻⁸) predicting GDF-15 from a genome-wide association study (GWAS) (n = 5440) and applied them to genetic studies of CAD (CARDIoGRAMplusC4D 1000 Genomes-based GWAS [n = 184,305]), type 2 diabetes (DIAGRAM [DIAbetes Genetics Replication And Meta-analysis; n = 898,130]), glycaemic traits (MAGIC [the Meta-Analyses of Glucose and Insulin-related traits Consortium; HbA_1c: n = 123,665; fasting glucose: n = 46,186]), BP, breast cancer and colorectal cancer (UK Biobank [n ≤ 401,447]), lipids (GLGC [Global Lipids Genetic Consortium; n ≤ 92,820]) and adiposity (GIANT [Genetic Investigation of ANthropometric Traits Consortium; n = 681,275]). Causal estimates were obtained using inverse variance weighting, taking into account correlations between SNPs. Sensitivity analyses included focusing on the lead SNP (rs888663) and validation for CAD in the UK Biobank and for breast cancer in the Breast Cancer Association Consortium.

Results

Using 5 SNPs, increased GDF-15 was associated with lower CAD (OR 0.93 per SD increase, 95% CI 0.87, 0.99) and breast cancer (OR 0.89 per SD increase, 95% CI 0.82, 0.96), with similar results from lead SNP analysis. However, the associations with CAD (OR 0.99 per SD increase, 95% CI 0.93, 1.04) and breast cancer (OR 0.97 per SD increase, 95% CI 0.94, 1.01) in the validation studies were not as apparent. GDF-15 was not associated with type 2 diabetes, glycaemic traits, CAD risk factors or colorectal cancer.

Conclusions/interpretation

There is no convincing evidence that GDF-15 reduces risk of CAD or breast or colorectal cancer. Whether the observed inverse association of metformin use with cancer risk is via other unexplored mechanistic pathways warrants further investigation.

Available only for authorised users

Douros A, Dell’Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S (2018) Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ 362:k2693. https://doi.org/10.1136/bmj.k2693 CrossRefPubMedPubMedCentral

Griffin SJ, Leaver JK, Irving GJ (2017) Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 60(9):1620–1629. https://doi.org/10.1007/s00125-017-4337-9 CrossRefPubMedPubMedCentral

Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35(12):2665–2673. https://doi.org/10.2337/dc12-0788 CrossRefPubMedPubMedCentral

Gerstein HC, Pare G, Hess S et al (2017) Growth differentiation factor 15 as a novel biomarker for metformin. Diabetes Care 40(2):280–283. https://doi.org/10.2337/dc16-1682 CrossRefPubMed

Natali A, Nesti L, Venturi E et al (2018) Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: a nested, case-control study. Diabetes Obes Metab 21(2):412–416. https://doi.org/10.1111/dom.13519 CrossRefPubMed

Taddei S, Virdis A (2010) Growth differentiation factor-15 and cardiovascular dysfunction and disease: malefactor or innocent bystander? Eur Heart J 31(10):1168–1171. https://doi.org/10.1093/eurheartj/ehq077 CrossRefPubMed

Li C, Wang X, Casal I et al (2016) Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J Cell Mol Med 20(8):1420–1426. https://doi.org/10.1111/jcmm.12830 CrossRefPubMedPubMedCentral

Holmes MV, Ala-Korpela M, Davey Smith G (2017) Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol 14(10):577–590. https://doi.org/10.1038/nrcardio.2017.78 CrossRefPubMedPubMedCentral

Cheung CL, Tan KCB, Au PCM, Li GHY, Cheung BMY (2019) Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: a Mendelian randomization study. EBioMedicine. 41:85–90. https://doi.org/10.1016/j.ebiom.2019.02.021 CrossRefPubMedPubMedCentral

10.

Jiang J, Thalamuthu A, Ho JE et al (2018) A meta-analysis of genome-wide association studies of growth differentiation factor-15 concentration in blood. Front Genet 9:97. https://doi.org/10.3389/fgene.2018.00097 CrossRefPubMedPubMedCentral

11.

Burgess S, Dudbridge F, Thompson SG (2016) Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med 35(11):1880–1906. https://doi.org/10.1002/sim.6835 CrossRefPubMed

12.

Nikpay M, Goel A, Won HH et al (2015) A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 47(10):1121–1130. https://doi.org/10.1038/ng.3396 CrossRefPubMedPubMedCentral

13.

Zhou W, Nielsen JB, Fritsche LG et al (2018) Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet 50(9):1335–1341. https://doi.org/10.1038/s41588-018-0184-y CrossRefPubMedPubMedCentral

14.

Sudlow C, Gallacher J, Allen N et al (2015) UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12(3):e1001779. https://doi.org/10.1371/journal.pmed.1001779 CrossRefPubMedPubMedCentral

15.

Denny JC, Bastarache L, Ritchie MD et al (2013) Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol 31(12):1102–1110. https://doi.org/10.1038/nbt.2749 CrossRefPubMedPubMedCentral

16.

Mahajan A, Taliun D, Thurner M et al (2018) Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 50(11):1505–1513. https://doi.org/10.1038/s41588-018-0241-6 CrossRefPubMedPubMedCentral

17.

Wheeler E, Leong A, Liu CT et al (2017) Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. PLoS Med 14(9):e1002383. https://doi.org/10.1371/journal.pmed.1002383 CrossRefPubMedPubMedCentral

18.

Dupuis J, Langenberg C, Prokopenko I et al (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42(2):105–116. https://doi.org/10.1038/ng.520 CrossRefPubMedPubMedCentral

19.

Global Lipids Genetics Consortium, Willer CJ, Schmidt EM et al (2013) Discovery and refinement of loci associated with lipid levels. Nat Genet 45(11):1274–1283. https://doi.org/10.1038/ng.2797 CrossRef

20.

Locke AE, Kahali B, Berndt SI et al (2015) Genetic studies of body mass index yield new insights for obesity biology. Nature 518(7538):197–206. https://doi.org/10.1038/nature14177 CrossRefPubMedPubMedCentral

21.

The Neale Lab UK Biobank GWAS. Available from http://www.nealelab.is/uk-biobank/ [Accessed: 22 Oct, 2018]

22.

Rosner B (1995) Fundamentals of biostatistics, 4th edn. Duxbury Press, Belmont, CA

23.

Pierce BL, Ahsan H, Vanderweele TJ (2011) Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 40(3):740–752. https://doi.org/10.1093/ije/dyq151 CrossRefPubMed

24.

Hemani G, Zheng J, Elsworth B, et al. (2018) The MR-Base platform supports systematic causal inference across the human phenome. Elife 7. https://doi.org/10.7554/eLife.34408

25.

Yavorska OO, Burgess S (2017) MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol 46(6):1734–1739. https://doi.org/10.1093/ije/dyx034 CrossRefPubMedPubMedCentral

26.

Michailidou K, Lindstrom S, Dennis J et al (2017) Association analysis identifies 65 new breast cancer risk loci. Nature 551(7678):92–94. https://doi.org/10.1038/nature24284 CrossRefPubMedPubMedCentral

27.

Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J (2017) A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med 36(11):1783–1802. https://doi.org/10.1002/sim.7221 CrossRefPubMedPubMedCentral

28.

Burgess S, Thompson SG (2017) Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 32(5):377–389. https://doi.org/10.1007/s10654-017-0255-x CrossRefPubMedPubMedCentral

29.

Burgess S (2014) Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol 43(3):922–929. https://doi.org/10.1093/ije/dyu005 CrossRefPubMedPubMedCentral

30.

Andersson C, Enserro D, Sullivan L et al (2016) Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study. Atherosclerosis 248:245–251. https://doi.org/10.1016/j.atherosclerosis.2016.02.013 CrossRefPubMedPubMedCentral

31.

Wallentin L, Hijazi Z, Andersson U et al (2014) Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 130(21):1847–1858. https://doi.org/10.1161/CIRCULATIONAHA.114.011204 CrossRefPubMed

32.

Pavo N, Wurm R, Neuhold S et al (2016) GDF-15 is associated with cancer incidence in patients with type 2 diabetes. Clin Chem 62(12):1612–1620. https://doi.org/10.1373/clinchem.2016.257212 CrossRefPubMed

33.

Liu T, Bauskin AR, Zaunders J et al (2003) Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63(16):5034–5040PubMed

34.

Kempf T, Eden M, Strelau J et al (2006) The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98(3):351–360. https://doi.org/10.1161/01.RES.0000202805.73038.48 CrossRefPubMed

35.

Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E (2011) Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 123(19):2101–2110. https://doi.org/10.1161/CIRCULATIONAHA.110.979740 CrossRefPubMedPubMedCentral

36.

Ago T, Sadoshima J (2006) GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res 98(3):294–297. https://doi.org/10.1161/01.RES.0000207919.83894.9d CrossRefPubMed

37.

Mullican SE, Lin-Schmidt X, Chin CN et al (2017) GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med 23(10):1150–1157. https://doi.org/10.1038/nm.4392 CrossRefPubMed

38.

Bauskin AR, Brown DA, Kuffner T et al (2006) Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 66(10):4983–4986. https://doi.org/10.1158/0008-5472.CAN-05-4067 CrossRefPubMed

39.

Bao X, Borne Y, Muhammad IF et al (2019) Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmo Diet and Cancer-Cardiovascular Cohort. Diabetologia. 62(1):78–86. https://doi.org/10.1007/s00125-018-4751-7 CrossRefPubMed

40.

Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ (2012) Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 35(2):446–454. https://doi.org/10.2337/dc11-1465 CrossRefPubMedPubMedCentral

41.

Nagi DK, Yudkin JS (1993) Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 16(4):621–629. https://doi.org/10.2337/diacare.16.4.621 CrossRefPubMed

42.

Campagnoli C, Berrino F, Venturelli E et al (2013) Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer 13(6):433–438. https://doi.org/10.1016/j.clbc.2013.08.012 CrossRefPubMed

43.

Song C, Burgess S, Eicher JD, O’Donnell CJ, Johnson AD (2017) Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease. J Am Heart Assoc 6(6). https://doi.org/10.1161/JAHA.116.004918

44.

Zhao JV, Schooling CM (2018) Coagulation factors and the risk of ischemic heart disease: a Mendelian randomization study. Circ Genom Precis Med 11(1):e001956. https://doi.org/10.1161/CIRCGEN.117.001956 CrossRefPubMed

45.

Schooling CM, Luo S, Au Yeung SL et al (2018) Genetic predictors of testosterone and their associations with cardiovascular disease and risk factors: A Mendelian randomization investigation. Int J Cardiol 267:171–176. https://doi.org/10.1016/j.ijcard.2018.05.051 CrossRefPubMedPubMedCentral

46.

Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289(24):3243–3253. https://doi.org/10.1001/jama.289.24.3243 CrossRefPubMed

47.

Wurtz P, Wang Q, Soininen P et al (2016) Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase. J Am Coll Cardiol 67(10):1200–1210. https://doi.org/10.1016/j.jacc.2015.12.060 CrossRefPubMedPubMedCentral

48.

Schooling CM, Au Yeung SL, Leung GM (2014) Why do statins reduce cardiovascular disease more than other lipid modulating therapies? Eur J Clin Investig 44(11):1135–1140. https://doi.org/10.1111/eci.12342 CrossRef

49.

Astle WJ, Elding H, Jiang T et al (2016) The allelic landscape of human blood cell trait variation and links to common complex disease. Cell 167(5):1415–1429 e1419. https://doi.org/10.1016/j.cell.2016.10.042 CrossRefPubMedPubMedCentral

50.

van der Harst P, Verweij N (2018) Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circ Res 122(3):433–443. https://doi.org/10.1161/CIRCRESAHA.117.312086 CrossRefPubMedPubMedCentral

Title: The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study
Authors: Shiu Lun Au Yeung
Shan Luo
C. Mary Schooling
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Metformin
Breast Cancer
Arterial Diseases
Colorectal Cancer
Colorectal Cancer
Type 2 Diabetes
Biomarkers
Published in: Diabetologia / Issue 9/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-019-4913-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 9/2019

Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes

Blood Mg2+ is more closely associated with hyperglycaemia than with hypertriacylglycerolaemia: the PREVEND study

Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals

Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study

Up front

Clinical aspects of heart failure in individuals with diabetes

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage